ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers

ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers

Source: 
Fierce Biotech
snippet: 

Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. On Saturday, the duo revealed data showing that enfortumab vedotin, along with Merck’s Keytruda, shrank 71% of tumors and wiped out 13% of them in patients with advanced urothelial cancer who had not undergone any other cancer treatment.